#Biogen buys into #Ionis’ #nusinersen after positive phase III trial – PMLiVE

Originally posted 2016-08-03 08:39:43.

SMA is caused by deterioration in the nerve cells connecting the brain and spinal cord to the body’s muscles, and Ionis was testing nusinersen in an infantile-onset form of the disease to see if it could improve motor function.The 13-month ENDEAR study revealed that patients taking nusinersen were significantly more likely to achieve an increase in motor function, measured using the Hammersmith Infant Neurological Examination scale, compared to those on placebo.

Esta entrada fue publicada en Sin categoría y etiquetada . Guarda el enlace permanente.

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *